Search clinical trials for: Sargramostim (GM-CSF)

Total 2405 results

Massachusetts General Hospital
Bayer; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Brigham...

Terminated

CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell | Lymphoma, Non-Hodgkin | Lymphoma, Diffuse

United States
BioVex Limited

Completed

Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer

Pancreatic Cancer

United States
Fundació Sant Joan de Déu

Completed

Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma

Effects of Immunotherapy | Neuroblastoma | Neoplasm, Residual

Spain
Maria Liljefors
Karolinska Institutet; Swedish Institute for Infectious Disease Control; Cyto...

Completed

Safety Study of DNA Vaccine Delivered by Intradermal Electroporation to Treat Colorectal Cancer (El-porCEA)

Colorectal Cancer

Sweden
Stanford University
Bayer

Terminated

Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer

Prostatic Neoplasms

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
National Cancer Institute (NCI)

Completed

A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas

Rhabdomyosarcoma | Ewing's Sarcoma

United States
Humanigen, Inc.

Completed

Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids (KB003-04)

Moderate-to-Severe Asthma

France, United Kingdom, United States, Australia, Poland, Ukraine
Vestre Viken Hospital Trust
Oslo University Hospital; University Hospital of North Norway; Helse Stavanger... and other collaborators

Recruiting

Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer (LUNGVAC)

Oncology | NSCLC Stage IV | NSCLC, Stage III

Norway
Hospital Universitario Dr. Jose E. Gonzalez

Unknown

Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation

Lymphoma, Non-Hodgkin | Myeloma | Lymphoma, Hodgkin | Stem Cell Transplant Complications

Mexico
University of Florida
Immunomic Therapeutics, Inc.

Terminated

RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.

Glioblastoma

United States
St. Jude Children's Research Hospital
Genzyme, a Sanofi Company

Completed

A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation

Acute Myeloid Leukemia | Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome

United States
Second Affiliated Hospital of Soochow University

Not yet recruiting

PRaG Therapy in Combination With Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study)

Pancreatic Ductal Adenocarcinoma
M.D. Anderson Cancer Center
The Vaccine Company

Terminated

Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)

Leukemia

United States
Ludwig Institute for Cancer Research
Cancer Research Institute, New York City; MedImmune LLC; Targovax ASA

Completed

A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

Colorectal Cancer | Ovarian Cancer | Appendiceal Cancer

United States
Second Affiliated Hospital of Soochow University

Not yet recruiting

PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites

Malignant Ascites
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI); The Skip Viragh Foundation

Completed

Adjuvant GVAX Vaccine Therapy in Patients With Pancreatic Cancer

Pancreatic Cancer

United States
M.D. Anderson Cancer Center
Bayer

Completed

FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Second Affiliated Hospital of Soochow University

Recruiting

Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)

Advanced Refractory Solid Tumors

China
Memorial Sloan Kettering Cancer Center

Terminated

3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma

Neuroblastoma

United States
Savara Inc.

Completed

Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis (IMPALA)

Autoimmune Pulmonary Alveolar Proteinosis

United States, United Kingdom, Denmark, Switzerland, Australia, Portugal, Italy, Greece, Netherlands, Japan, Germany, France, Israel, Korea, Republic of, Russian Federation, Slovakia, Spain, Turkey
University of Washington
United States Department of Defense

Recruiting

A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer

Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8

United States
Beth Israel Deaconess Medical Center
Bristol-Myers Squibb; Dana-Farber Cancer Institute

Terminated

Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma

Multiple Myeloma

United States
National Institute of Allergy and Infectious Diseases...

Completed

Adjuvant Cytokine Therapy to Treat Pulmonary Mycobacterium Avium Complex Infection

Mycobacterium Avium-Intracellulare Infection

United States
The First Affiliated Hospital of Xiamen University

Unknown

SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy

Lung Cancer Metastatic

China
United Therapeutics

Completed

ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

Neuroblastoma

United States
Second Affiliated Hospital of Soochow University

Not yet recruiting

PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.

Metastatic Solid Tumor
Cardiff University
Experimental Cancer Medicine Centres; Leukaemia & Lymphoma Research Group

Completed

A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. (AML18 Pilot)

High Risk Myelodysplastic Syndrome | Acute Myeloid Leukaemia

United Kingdom
Gliknik Inc.

Completed

Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity

Squamous Cell Carcinoma of the Oral Cavity

United States, Hungary, Ukraine, Russian Federation, Serbia, Poland, Spain
Uppsala University

Unknown

A Comparative Study of Six Methods to Measure Human Contrast Vision

Methods to Measure Contrast Vision

Sweden
Charite University, Berlin, Germany

Terminated

Action of Caffeinated and Decaffeinated Espresso on Autonomic Function

Influence of Espresso on Heart Rate Variability

Germany
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected Individuals

HIV Infections

United States
Rampart Health, L.L.C.

Recruiting

A Phase 2 Trial for Patients With Metastatic Solid Cancer

Metastatic Cancer

United States
Stanford University

Recruiting

Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging

Cervix Cancer | Endometrial Cancer

United States
Immatics Biotechnologies GmbH

Completed

IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101) (IMA910-101)

Colorectal Carcinoma

United Kingdom, Romania, Belgium, Bulgaria, Germany, Hungary, Latvia, Poland, Serbia
M.D. Anderson Cancer Center
Novartis

Completed

High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)

Leukemia, Myeloid, Chronic

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer

Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI); Eli Lilly and Company; Kanisa Pharmaceuticals

Completed

Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia

Myelodysplastic Syndromes | Leukemia

United States, Israel
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

Multiple Myeloma

United States
Ultimovacs ASA
Oslo University Hospital

Active, not recruiting

Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma

Malignant Melanoma

Norway
University of California, San Francisco
Genzyme, a Sanofi Company

Completed

Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC)

Prostate Cancer

United States
Genzyme, a Sanofi Company

Completed

Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662).

Multiple Myeloma | Autologous Transplantation
Sidney Kimmel Comprehensive Cancer Center at Johns...

Completed

FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer

Metastatic Pancreatic Adenocarcinoma

United States
University of Florida
Oligo Nation, Inc

Not yet recruiting

ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients (ADAGiO)

Recurrent Oligodendroglioma | Progressive Oligodendroglioma

United States
Second Affiliated Hospital of Soochow University

Not yet recruiting

The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0)

Carcinoma | Solid Tumor

China
National Cancer Institute (NCI)

Completed

Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation

Multiple Myeloma | Graft vs Host Disease

United States
Neodent

Active, not recruiting

Implant Retained Rehabilitation With Surgical and Prosthetic Digital Workflow

Jaw, Edentulous, Partially

Brazil
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma

Recurrent Neuroblastoma | Disseminated Neuroblastoma | Regional Neuroblastoma

United States
University Hospital Inselspital, Berne

Completed

Peg-Granulocyte-Colony Stimulating Factor (GCSF) for Coronary Collateral Growth in Coronary Artery Disease Patients

Coronary Artery Disease

Switzerland

Search clinical trials for: Sargramostim (GM-CSF)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations